Key Points
- CFO Scott Burrows sold 7,500 Spyre Therapeutics shares at an average price of $95.57, totaling $716,775, under a pre-arranged Rule 10b5-1 trading plan. He retains 97,994 shares valued at approximately $9.4 million.
- Spyre reported a quarterly loss of $0.36 per share, beating analysts’ expected loss of $0.76, while continuing to advance its Phase 2 pipeline and upcoming clinical data readouts.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $110.15; Guggenheim and Wedbush both recently raised their targets to $130.
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 7,500 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $95.57, for a total transaction of $716,775.00. Following the sale, the chief financial officer directly owned 97,994 shares in the company, valued at approximately $9,365,286.58. This represents a 7.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Spyre Therapeutics Trading Down 0.6%
SYRE stock opened at $104.35 on Thursday. The firm has a 50 day moving average of $89.91 and a 200-day moving average of $64.66. The company has a market cap of $9.18 billion, a price-to-earnings ratio of -53.51 and a beta of 3.03. Spyre Therapeutics, Inc. has a 12-month low of $14.51 and a 12-month high of $108.14.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.40. Sell-side analysts forecast that Spyre Therapeutics, Inc. will post -2.86 earnings per share for the current fiscal year.
Spyre Therapeutics News Summary
Here are the key news stories impacting Spyre Therapeutics this week:
- Positive Sentiment: Spyre reported a second-quarter loss of $0.36 per share, substantially narrower than the analyst consensus estimate of $0.76. The earnings beat suggests better-than-expected cost management and helped improve investor sentiment. SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses
- Positive Sentiment: The company highlighted progress across its Phase 2 development pipeline and upcoming clinical data readouts. These catalysts are particularly important for Spyre because the company remains focused on advancing its therapies rather than generating near-term profits. Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Positive Sentiment: Wedbush raised its price target from $100 to $130 and maintained an “Outperform” rating. Guggenheim also increased its target from $115 to $130 and kept a “Buy” rating, signaling that analysts see additional upside from Spyre’s pipeline and upcoming clinical milestones. Analyst price-target updates
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. Citigroup boosted their price objective on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the stock a "buy" rating in a research report on Wednesday, May 6th. Stifel Nicolaus lifted their target price on shares of Spyre Therapeutics from $92.00 to $107.00 and gave the stock a "buy" rating in a research report on Wednesday, May 6th. Guggenheim upped their price target on shares of Spyre Therapeutics from $115.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday. Robert W. Baird set a $120.00 price target on shares of Spyre Therapeutics in a research report on Wednesday. Finally, Leerink Partners raised their price objective on shares of Spyre Therapeutics from $49.00 to $106.00 and gave the stock an "outperform" rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $110.15.
Read Our Latest Report on SYRE
Institutional Trading of Spyre Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in SYRE. Handelsbanken Fonder AB purchased a new stake in Spyre Therapeutics during the 2nd quarter worth about $2,308,000. GAMMA Investing LLC lifted its holdings in Spyre Therapeutics by 26.8% in the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $59,000 after purchasing an additional 140 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Spyre Therapeutics during the 1st quarter worth about $993,000. Perceptive Advisors LLC grew its holdings in shares of Spyre Therapeutics by 23.3% during the first quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company's stock worth $190,826,000 after buying an additional 714,000 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Spyre Therapeutics by 192.6% during the first quarter. Bank of America Corp DE now owns 1,228,093 shares of the company's stock worth $61,945,000 after buying an additional 808,366 shares in the last quarter. 80.39% of the stock is currently owned by hedge funds and other institutional investors.
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
